Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/phpp.12900 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vitiligo is a common pigment disorder of the skin resulting in destruction of melanocytes. Non-segmental vitiligo (NSV) is an autoimmune disorder. The etiopathogenesis of segmental vitiligo (SV) remains incompletely understood.
View Article and Find Full Text PDFClinical Prognostic Factors Predicting Outcomes in Vitiligo: A Scoping Review.
Pigment Cell Melanoma Res
September 2025
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
The progression of non-segmental vitiligo is highly unpredictable, exhibiting various phenotypes that can range from rapid progression to stability. Due to limited literature, we conducted a scoping review to identify factors influencing the outcomes of non-segmental vitiligo, focusing on disease progression, extent, and response to therapy. This review adhered to PRISMA-ScR guidelines and involved searching the PubMed and Google Scholar databases for studies published in English from January 1995 to December 2023.
View Article and Find Full Text PDFCullin-3 and Regulatory Biomolecules Profiling in Vitiligo: Integrated Docking, Clinical, and In Silico Insights.
Biomolecules
July 2025
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt.
Background: Vitiligo, a chronic depigmentation disorder driven by oxidative stress and immune dysregulation, remains poorly understood mechanistically. The Keap1/NRF2/ARE pathway is critical for melanocyte protection against oxidative damage; however, the role of Cullin-3 (CUL3), a scaffold for E3 ubiquitin ligases that regulate NRF2 degradation, and its interplay with inflammatory mediators in vitiligo pathogenesis are underexplored. This study investigates CUL3, NRF2, and the associated regulatory networks in vitiligo, integrating clinical profiling and computational docking to identify therapeutic targets.
View Article and Find Full Text PDFClinicodemographic Features and Usage of Oral Immunosuppressive Agents in Childhood and Adolescent Vitiligo: Retrospective Chart Review From a Tertiary Care Centre in Northern India.
Int J Dermatol
July 2025
Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Background: Vitiligo is a common acquired depigmentation disorder with significant psychosocial implications, especially in pediatric populations. Despite the availability of topical treatments, systemic immunosuppressive agents are increasingly being explored for progressive disease. However, limited data exist regarding their efficacy and safety in pediatric vitiligo.
View Article and Find Full Text PDFEfficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo.
JAAD Int
October 2025
Department of Dermatology, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Medical Center of Soochow University, Suzhou, Jiangsu, China.